Photodynamic therapy vs. imiquimod 5% cream as skin cancer preventive strategies in patients with field changes: a randomized intraindividual comparison study
Journal of the European Academy of Dermatology and Venereology, 2015•Wiley Online Library
Background Actinic damage is responsible for the development of multiple, recurrent non‐
melanoma skin cancers (NMSC s), including actinic keratoses (AK s). Photodynamic therapy
(PDT) and imiquimod cream (IMIQ) 5% are recommended as field‐directed treatment
options. Objectives To compare efficacy and safety of methyl aminolevulinate (MAL)‐PDT vs.
IMIQ 5% in the prevention of new NMSC s development patients with field changes.
Methods Patients with field cancerization of the face or scalp were randomized to receive …
melanoma skin cancers (NMSC s), including actinic keratoses (AK s). Photodynamic therapy
(PDT) and imiquimod cream (IMIQ) 5% are recommended as field‐directed treatment
options. Objectives To compare efficacy and safety of methyl aminolevulinate (MAL)‐PDT vs.
IMIQ 5% in the prevention of new NMSC s development patients with field changes.
Methods Patients with field cancerization of the face or scalp were randomized to receive …
Background
Actinic damage is responsible for the development of multiple, recurrent non‐melanoma skin cancers (NMSCs), including actinic keratoses (AKs). Photodynamic therapy (PDT) and imiquimod cream (IMIQ) 5% are recommended as field‐directed treatment options.
Objectives
To compare efficacy and safety of methyl aminolevulinate (MAL)‐PDT vs. IMIQ 5% in the prevention of new NMSCs development patients with field changes.
Methods
Patients with field cancerization of the face or scalp were randomized to receive MAL‐PDT on one side, and IMIQ 5% on the mirror field. The primary endpoint was the number of new lesions on the treated fields during a 12‐month follow‐up period. Secondary assessments included adverse events and patient preference.
Results
Forty‐four patients completed the study. MAL‐PDT and IMIQ did not differ concerning the primary endpoint, as there was no statistically significant difference in terms of development of new NMSCs at any point of follow‐up. Both treatment regimens were safe and well tolerated. Patients' preference based on the procedure, response rates and future choice favoured MAL‐PDT.
Conclusions
MAL‐PDT and IMIQ 5% are safe and well‐tolerated treatments that equally prevent development of new AKs in patients suffering from field changes. MAL‐PDT treatment appears to be superior in terms of patients' preference.
Wiley Online Library